How Ph.D was paid
$25.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Other | Total |
|---|---|---|---|---|---|
| Dr. Jerel Banks, M.D. Ph.DChairman and Chief Executive Officer | $661,100 | $366,850 | $24,795,540 | $41,546 | $25,865,036 |
| Megan BostonChief Financial Officer, Secretary | $445,610 | $175,000 | $7,728,480 | $250,203 | $8,599,293 |
| Sophie MukadamChief Operating Officer | $340,846 | $200,000 | $3,175,800 | $58,747 | $3,775,393 |
What changed and why
- $25.9M$25,865,036 CEO total compensation included $24,795,540 in option awards.
- $7.7M$7,728,480 in option awards comprised Megan Boston’s largest compensation component.
- $3.2M$3,175,800 in option awards comprised Sophie Mukadam’s largest compensation component.
- 55%55% was Dr. Banks’ target bonus percentage for fiscal 2025 performance.
- 16 quarterly installments govern the vesting of the December 2024 option grants.
- $500K$500,000 was Sophie Mukadam’s annualized base salary effective January 1, 2025.
Other Benitec Biopharma proxy statements
- 2026 proxy statement
Dr. Jerel Banks, M.D. Ph.D paid $6.5M (-75% on the year).
Filed Oct 20, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.